The UK and US have reached a key bilateral deal that will ensure no duties on UK pharmaceutical exports entering the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to increase spending on pharmaceuticals through the NHS. This commitment ensures that tariffs on these key products will stay at nothing for a duration of the next three years.
This agreement follows earlier statements to dramatically increase import taxes on branded drug products, with increases mentioned as high as 100%.
"This arrangement between the Britain reinforces the global environment for cutting-edge drugs and brings much-needed equity to American-British pharmaceutical trade," a release noted.
Commercial Impact
Medicines represent one of the Britain's largest goods shipped to the US, which is easily the primary buyer for large British pharmaceutical firms.
Export figures indicate that in the 12 months to the end of the third quarter, the UK exported drugs worth billions to the US. This amount accounted for nearly one-fifth of all goods exports in that period.
"This deal safeguards jobs, increases funding and facilitates the UK to establish itself as a international leader for life sciences," a government official remarked.
Key British Pledges
The pact involves several notable commitments from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a goal to raise total public funding on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to prevent overspending will be capped at 15%. In the past, repayments were more than twenty percent.
Recent Tensions
The pact follows a protracted tension between the drug companies and the UK government over drug pricing and approval rates.
The disagreement were intensified by arguments that US consumers were paying a premium for the equivalent treatments than patients in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been delayed or cancelled, while substantial funding commitments have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS must increase expenditure on drugs, noting that its spending on drugs had declined as a share of its overall budget over the last ten years.